The medical device firm reports Q2 2026 revenue of $22.8 million, aligning with expectations as commercial efforts progress.
Pulmonx maintained its 2026 revenue outlook of $90M to $92M, targeting a gross margin of approximately 76%. The company reported Q2 2026 revenue of $22.8 million, matching internal projections as it works to restore commercial momentum.
The guidance follows a period of strategic adjustments aimed at regaining market traction. Management indicated that performance remains on track with earlier forecasts, though no prior quarterly figures were provided for direct comparison.
Shares showed limited movement in after-hours trading, reflecting investor focus on long-term execution rather than short-term results.